Sunday, January 23, 2005
Contributors
Previous Posts
- The histopathological differential diagnosis of gastrointestinal stromal tumours
- Novel Kinase Inhibitors for the Treatment of Imatinib Mesylate–Resistant Gastrointestinal Stromal Tumors
- GIST prognosis based on histology
- Antibodies and kits for KIT
- GI stromal tumors: a model for what's coming
- High efficacy of imatinib for recurrent gastrointestinal stromal tumor in the jejunum: a case report
- Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia
- The GIST of targeted cancer therapy: a tumor (gastronitestinal stromal tumor), a mutated gene (c-kit, and a molecular inhibitor (STI571)
- Upper gastrointestinal hemorrhage due to duodenal stromal tumor
- Giant malignant gastrointestinal stromal tumors: Recurrence and effects of treatment with STI-571
0 Comments:
Post a Comment
<< Home